Matching-adjusted indirect comparison of benralizumab versus interleukin-5 inhibitors for the treatment of severe asthma: a systematic review

Benralizumab is an interleukin-5 receptor α-directed cytolytic monoclonal antibody that directly depletes eosinophils. Its relative efficacy versus other IL-5-targeted treatments for patients with severe, uncontrolled asthma is not yet fully characterised. We performed a matching-adjusted indirect c...

Descripción completa

Detalles Bibliográficos
Autores principales: Bourdin, Arnaud, Husereau, Don, Molinari, Nicolas, Golam, Sarowar, Siddiqui, Mohd Kashif, Lindner, Leandro, Xu, Xiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6277255/
https://www.ncbi.nlm.nih.gov/pubmed/30309978
http://dx.doi.org/10.1183/13993003.01393-2018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6277255/
https://www.ncbi.nlm.nih.gov/pubmed/30309978
http://dx.doi.org/10.1183/13993003.01393-2018

Ejemplares similares